9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 126 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: I227|2016-002286-60 Study First Received: May 24, 2016 Last Updated: March 27, 2017 Estimated Primary Completion Date: May 2019 Primary Outcome Measures: Progression free survival measured as time from randomization to first observation of objective disease relapse or progression|Number and severity of adverse events|Overall Survival|Quality of Life using EORTC QLQ-C30|Response rate compared using Fisher's exact test Sponsors and Collaborators: Canadian Cancer Trials Group|National Cancer Institute, Naples|Merck Sharp & Dohme Corp. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02784171...

Continue reading

Autologous Dendritic Cell Vaccination in Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 20 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CCRG13-002 Study First Received: December 7, 2015 Last Updated: January 24, 2017 Estimated Primary Completion Date: October 2020 Primary Outcome Measures: Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity Sponsors and Collaborators: University Hospital, Antwerp Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02649829...

Continue reading

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Condition Mesothelioma Estimated Enrollment: 600 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CA209-743|2016-001859-43 Study First Received: August 31, 2016 Last Updated: April 17, 2017 Estimated Primary Completion Date: October 2020 Primary Outcome Measures: Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy Sponsors and Collaborators: Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02899299...

Continue reading

MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 50 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MARS2 Study First Received: December 20, 2013 Last Updated: April 12, 2016 Estimated Primary Completion Date: May 2017 Primary Outcome Measures: Ability to randomise 50 patients|Survival from the time point of randomisation|Quality of life as assessed using QLQ 30 and LC-13 scales Sponsors and Collaborators: Royal Brompton & Harefield NHS Foundation Trust|Cancer Research UK|Papworth Hospital NHS Foundation Trust Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02040272...

Continue reading

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Condition Lung Cancer|Mesothelioma Estimated Enrollment: 2000 Age Group: 30 Years to 85 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case Control Study ID Numbers: Asbestos Screening Study Study First Received: September 12, 2005 Last Updated: March 17, 2016 Estimated Primary Completion Date: March 2017 Primary Outcome Measures: Sponsors and Collaborators: University Health Network, Toronto Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00188890...

Continue reading

Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma

Condition Pleural Mesothelioma Estimated Enrollment: 10 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: TILs-003-Meso Study First Received: April 8, 2015 Last Updated: May 31, 2016 Estimated Primary Completion Date: June 2025 Primary Outcome Measures: Total number of adverse events for each event reported and the severity and attribution to study therapy of each event|Percentage of patients with a clinical response to the study treatment Sponsors and Collaborators: University Health Network, Toronto Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02414945...

Continue reading

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Condition Mesothelioma Estimated Enrollment: 336 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment Study ID Numbers: 22864|2016-003111-35|CA290841|A21400 Study First Received: February 10, 2017 Last Updated: April 11, 2017 Estimated Primary Completion Date: June 2021 Primary Outcome Measures: Overall survival|modified RECIST or RECIST 1.1 - progression free survival|modified RECIST or RECIST 1.1 - overall response rate|EQ-5D-5L|CTCAE V4.03|Health resource use questionnaire Sponsors and Collaborators: University of Southampton|University of Leicester|University of Sheffield|Queen Mary University of London|Queen's University, Belfast|Velindre NHS Trust|Beatson West of Scotland Cancer Centre Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT03063450...

Continue reading

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 6 Age Group: 18 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2014_01|2015-001554-15 Study First Received: January 14, 2016 Last Updated: February 1, 2017 Estimated Primary Completion Date: November 2017 Primary Outcome Measures: Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Number of responders or stable patients after surgery|Progression-free survival (PFS)|Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30) Sponsors and Collaborators: University Hospital, Lille|Institut National de la Santé Et de la Recherche...

Continue reading

Intrapleural Cryotherapy for Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 15 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 14-008715 Study First Received: May 14, 2015 Last Updated: December 20, 2016 Estimated Primary Completion Date: June 2017 Primary Outcome Measures: Number of Participants with Adverse Events|Mean Number of Tumor Infiltrating Immune Cells as Measured by Immunohistochemistry on Participant Tissue Samples Sponsors and Collaborators: Mayo Clinic|CSA Medical, Inc. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02464904...

Continue reading

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma

Condition Advanced Malignant Pleural Mesothelioma Estimated Enrollment: 100 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment Study ID Numbers: NGR019|2010-023614-31 Study First Received: May 19, 2011 Last Updated: May 27, 2016 Estimated Primary Completion Date: December 2016 Primary Outcome Measures: Progression-Free Survival (PFS)|Overall survival (OS)|Tumor response|Safety and Toxicity according to NCI-CTCAE criteria(version 4.03)|Quality of life (QoL) according to Lung Cancer Symptom Scale Sponsors and Collaborators: MolMed S.p.A. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01358084...

Continue reading